Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

CDS023093

Sigma-Aldrich

Nilotinib

Sinonimo/i:

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide, 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide, 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C28H22F3N7O
Numero CAS:
641571-10-0
Peso molecolare:
529.52
Numero MDL:
MFCD09833716
Codice UNSPSC:
12352200
ID PubChem:
329796354

Descrizione

AldrichCPR

Stato

solid

Temperatura di conservazione

-10 to -25°C

Stringa SMILE

CC1=CN(C2=CC(NC(C3=CC=C(C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3)C)=O)=CC(C(F)(F)F)=C2)C=N1

InChI

1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
HHZIURLSWUIHRB-UHFFFAOYSA-N

Informazioni sul gene

human ... ABL1(25)

Descrizione generale

Nilotinib is an aminopyrimidine-derivative that can be used as a selective inhibitor of tyrosine kinase receptors. It also has a role as an antineoplastic agent and an anticoronaviral agent.

Altre note

Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of unique chemicals. Sigma-Aldrich does not collect analytical data for this product. Buyer assumes responsibility to confirm product identity and/or purity. All sales are final.

NOTWITHSTANDING ANY CONTRARY PROVISION CONTAINED IN SIGMA-ALDRICH′S STANDARD TERMS AND CONDITIONS OF SALE OR AN AGREEMENT BETWEEN SIGMA-ALDRICH AND BUYER, SIGMA-ALDRICH SELLS THIS PRODUCT "AS-IS" AND MAKES NO REPRESENTATION OR WARRANTY WHATSOEVER WITH RESPECT TO THIS PRODUCT, INCLUDING ANY (A) WARRANTY OF MERCHANTABILITY, (B) WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR (C) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H372,H413

Classi di pericolo

Aquatic Chronic 4 - STOT RE 1

Organi bersaglio

Liver,Kidney,gallbladder

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Nilotinib impurity A European Pharmacopoeia (EP) Reference Standard

Y0002103

Nilotinib impurity A

Metoclopramide VETRANAL®, analytical standard

Supelco

32473

Metoclopramide

Erlotinib hydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML2156

Erlotinib hydrochloride

Lapatinib ≥98% (HPLC)

Sigma-Aldrich

SML2259

Lapatinib

Lapatinib

Sigma-Aldrich

CDS022971

Lapatinib

Nicardipine hydrochloride powder, ≥98%

Sigma-Aldrich

N7510

Nicardipine hydrochloride

Gefitinib ≥98% (HPLC)

Sigma-Aldrich

SML1657

Gefitinib

A Hochhaus et al.
Leukemia, 31(7), 1525-1531 (2017-02-22)
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR
Fabienne Lamballe et al.
Oncotarget, 7(46), 74747-74767 (2016-10-13)
The cytoplasmic tyrosine kinase ABL exerts positive or negative effects in solid tumours according to the cellular context, thus functioning as a "switch modulator". The therapeutic effects of drugs targeting a set of signals encompassing ABL have been explored in
Hans Gelderblom et al.
The Lancet. Oncology, 19(5), 639-648 (2018-03-25)
Pigmented villonodular synovitis (alternatively known as diffuse-type giant cell tumour) is a rare, locally aggressive tumour driven by a specific translocation resulting in the overexpression of colony-stimulating factor 1 (CSF1). CSF1 receptor (CSF1R) inhibitors (ie, tyrosine kinase inhibitors and antibodies)
Konstantin Byrgazov et al.
Oncotarget, 7(47), 78083-78094 (2016-11-02)
Point mutations in the ABL1 kinase domain are an important mechanism of resistance to tyrosine kinase inhibitors (TKI) in BCR-ABL1-positive and, as recently shown, BCR-ABL1-like leukemias. The cell line Ba/F3 lentivirally transduced with mutant BCR-ABL1 constructs is widely used for
Hélène Bon et al.
Nephron, 142(4), 328-350 (2019-05-03)
Tubulointerstitial fibrosis is a key feature of chronic kidney diseases leading to renal failure. It is characterised by the infiltration of fibroblasts and aberrant accumulation of extracellular matrix (ECM) proteins, which are associated with progressive loss of renal function. Integrins
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.